Profiling the spatial relationships between effector PD-1+ CD4+ T cells, tumor cells, and immunosuppressive Tregs allowed us to derive the SpatialScore—a clinically useful biomarker that correlated strongly with pembrolizumab response in CTCL. The gene discussed is CD4; the disease is neoplasm.